Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

CJC-1295 (with DAC) vs Ipamorelin

Q: What is the difference between CJC-1295 (with DAC) and Ipamorelin?

CJC-1295 (with DAC) is a Growth Hormone Secretagogue compound (Subcutaneous route) - GHRH analog with Drug Affinity Complex — albumin binding extends half-life to ~1 week. Ipamorelin is a Growth Hormone Secretagogue compound (Subcutaneous route) - Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration.

Q: Which has a longer half-life, CJC-1295 (with DAC) or Ipamorelin?

CJC-1295 (with DAC) has the longest published plasma half-life (~7.0 days (168 h)), compared with Ipamorelin (2 h).

Q: How often is each compound dosed in the research literature?

CJC-1295 (with DAC): once weekly at a published dose range of 1–2 mg; Ipamorelin: once daily at a published dose range of 0.2–0.3 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy CJC-1295 (with DAC) and Ipamorelin for research use?

Yes - CJC-1295 (with DAC), Ipamorelin are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

CJC-1295 (WITH DAC)

CJC-1295 (with DAC)

Growth Hormone Secretagogue

IPAMORELIN

Ipamorelin

Growth Hormone Secretagogue

Key research differences

CJC-1295 (with DAC) Ipamorelin Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Development status Research peptide Research peptide Published half-life ~7.0 days (168 h) 2 h Research distinction GHRH analog with Drug Affinity Complex — albumin binding extends half-life to ~1 week Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration

Published research parameters

CJC-1295 (with DAC) CJC-1295, DAC:GRF View CJC-1295 (with DAC) → Ipamorelin NNC 26-0161 View Ipamorelin → Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Class Growth Hormone Secretagogue Growth Hormone Secretagogue Plasma half-life ~7.0 days (168 h) 2 h Time to Cmax 12 h ~30 min Development status Research peptide Research peptide Study context Peer-reviewed human PK Educational estimate Primary publications Teichman SL et al., J Clin Endocrinol Metab 91:799 (half-life 5.8–8.1 d) (2006) Raun K et al., Eur J Endocrinol 139:552 (1998) Summary GHRH analog with Drug Affinity Complex — albumin binding extends half-life to ~1 week. Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration.

View published study parameters

CJC-1295 (with DAC) CJC-1295, DAC:GRF View CJC-1295 (with DAC) → Ipamorelin NNC 26-0161 View Ipamorelin → Route in published studies Subcutaneous Subcutaneous Published study interval Once weekly Once daily Published dose range 1–2 mg 0.2–0.3 mg Published study regimen No published study ladder No published study ladder

Source references

Teichman SL et al.

2006

Teichman SL et al., J Clin Endocrinol Metab 91:799 (half-life 5.8–8.1 d) (2006)

Raun K et al.

1998

Raun K et al., Eur J Endocrinol 139:552 (1998)

Frequently asked questions

What is the difference between CJC-1295 (with DAC) and Ipamorelin?

Which has a longer half-life, CJC-1295 (with DAC) or Ipamorelin?

How often is each compound dosed in the research literature?

Can you buy CJC-1295 (with DAC) and Ipamorelin for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research